Article Details

In $2.6B cancer deal, Seagen bets China's first homemade ADC can challenge Roche, AZ-Daiichi

Retrieved on: 2021-08-09 15:22:30

Tags for this article:

Click the tags to see associated articles and topics

In $2.6B cancer deal, Seagen bets China's first homemade ADC can challenge Roche, AZ-Daiichi. View article details on HISWAI: https://www.fiercepharma.com/pharma/taking-aim-at-roche-and-astra-daiichi-seagen-bets-up-to-2-6b-china-s-first-home-made-adc

Excerpt

... direct threat to Roche's Kadcyla and AstraZeneca and Daiichi Sankyo's Enhertu in the HER2 cancer field, where the top players are reaping billions.

Article found on: www.fiercepharma.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up